compos
multipl
subunit
bind
variou
host
cell
receptor
includ
sulfat
glycolipid
attach
pneumonia
induc
gener
superoxid
radic
inhibit
catalas
lead
oxid
stress
host
cell
pneumonia
infect
also
induc
product
proinflammatori
cytokin
tumor
necrosi
factor
tnf
interleukin
il
part
engag
tolllik
receptor
tlr
infect
ultim
lead
variou
patholog
chang
respiratori
epithelium
includ
loss
cilia
metabol
derang
slough
immun
respons
pneumonia
multifactori
includ
innat
signal
tlr
opson
phagocytosi
adapt
immun
respons
antibodi
product
activ
th
cell
clinic
individu
clear
bacteria
wherea
other
partial
erad
lead
chronic
lowlevel
infect
evid
suggest
establish
allerg
airway
inflamm
may
hinder
clearanc
pathogen
use
mous
model
wu
colleagu
found
express
downregul
presenc
allerg
inflamm
pneumonia
infect
recent
wu
colleagu
also
report
lowdos
pneumonia
infect
enhanc
underli
allerg
lung
inflamm
augment
thelper
respons
allergen
contrast
highdos
pneumonia
infect
attenu
allerg
respons
furthermor
hoek
colleagu
demonstr
rodent
mast
cell
releas
cocultur
pneumonia
suggest
pneumonia
infect
may
promot
allerg
inflamm
lastli
chu
colleagu
found
pneumonia
infect
allergensensit
mice
result
increas
airway
collagen
deposit
anim
studi
suggest
pneumonia
infect
lung
may
play
role
asthma
develop
patholog
diseas
activ
chlamydophila
pneumonia
oblig
intracellular
pathogen
transmit
persontoperson
contact
respiratori
secret
incub
period
week
mani
individu
remain
asymptomat
c
pneumonia
infect
wherea
other
develop
sinopulmonari
diseas
c
pneumonia
exist
form
replic
reticul
bodi
infect
elementari
bodi
releas
extracellular
environ
elementari
bodi
interact
respiratori
epitheli
cell
lead
phagosom
format
subsequ
intracellular
replic
lung
c
pneumonia
infect
shown
increas
endotheli
nuclear
factor
nf
kb
subsequ
upregul
inflammatori
adhes
molecul
chemokin
plateletderiv
growth
factor
epitheli
cell
adhes
molecul
also
increas
lead
influx
inflammatori
cell
addit
c
pneumonia
may
particip
airway
remodel
promot
fibroblast
prolifer
driven
part
growth
factor
similarli
pneumonia
infect
immun
respons
c
pneumonia
multifactori
includ
innat
humor
cellmedi
immun
mechan
pulmonari
infect
c
pneumonia
may
also
contribut
asthma
develop
diseas
patholog
chen
colleagu
infect
balbc
mice
c
pneumonia
intranas
found
repeat
infect
increas
gene
express
airway
subepitheli
basement
membran
thicken
featur
atop
asthma
use
murin
model
blasi
colleagu
demonstr
intranas
infect
c
pneumonia
result
sustain
airway
hyperrespons
measur
methacholin
challeng
barometr
plethysmographi
recent
bulut
colleagu
establish
c
pneumonia
heat
shock
protein
contribut
develop
acut
lung
inflamm
mice
conclud
may
play
role
acut
chronic
lung
inflamm
anim
studi
suggest
mechan
c
pneumonia
infect
lung
may
contribut
develop
patholog
manifest
asthma
signific
limit
challeng
diagnos
atyp
bacteri
infect
lung
current
techniqu
includ
cultur
antigen
detect
serolog
polymeras
chain
reaction
pcr
cultur
atyp
bacteria
timeintens
technic
difficult
method
detect
includ
enzym
immunoassay
eia
enzymelink
immunosorb
assay
elisa
microimmunofluoresc
c
pneumonia
detect
igm
antibodi
typic
week
infect
fourfold
increas
igg
antibodi
convalesc
sera
suggest
acut
infect
pneumonia
eia
frequent
use
compar
acut
convalesc
sera
look
fourfold
increas
antibodi
titer
pcr
detect
atyp
bacteria
sensit
lack
standard
avail
addit
correl
differ
diagnost
test
fairli
low
definit
diagnosi
may
requir
invas
tissu
sampl
infrequ
perform
due
lack
standard
test
discord
detect
methodolog
limit
abil
accur
detect
atyp
bacteri
infect
lung
subsequ
affect
conclus
drawn
avail
studi
evalu
role
atyp
bacteria
asthma
emerg
techniqu
multiplex
pcr
microfluid
platform
pneumonia
may
provid
method
fast
sensit
diagnosi
mani
studi
atyp
bacteri
infect
posit
correl
acut
asthma
exacerb
year
report
potenti
link
atyp
infect
asthma
berkovich
colleagu
examin
children
asthma
found
evid
pneumonia
infect
asthma
exacerb
johnston
martin
review
studi
look
c
pneumonia
pneumonia
infect
acut
asthma
flare
found
studi
demonstr
associ
infect
exacerb
sever
studi
support
role
atyp
bacteri
infect
asthma
exacerb
discuss
studi
mild
moder
adult
asthmat
acut
exacerb
allegra
colleag
report
subject
seroconvert
one
viral
atyp
bacteri
pathogen
evidenc
fourfold
increas
titer
studi
period
evid
atyp
bacteri
infect
found
subject
caus
c
pneumonia
contrast
subject
acut
exacerb
evid
viral
infect
limit
studi
pcr
methodolog
avail
diagnosi
miyashita
colleagu
evalu
adult
asthma
exacerb
match
control
found
signific
increas
c
pneumonia
infect
asthmat
group
well
increas
c
pneumoniaespecif
igg
iga
asthmat
compar
control
investig
subsequ
conclud
c
pneumonia
infect
may
contribut
asthma
exacerb
furthermor
cunningham
colleagu
evalu
children
asthma
obtain
nasal
aspir
sera
signific
decreas
peak
flow
increas
respiratori
symptom
note
children
recurr
exacerb
like
remain
pcrposit
c
pneumonia
time
greater
level
c
pneumoniaespecif
iga
level
cunningham
colleagu
postul
higher
antibodi
respons
c
pneumonia
subject
increas
asthma
flare
compar
fewer
exacerb
could
repres
increas
preval
infect
differenti
immun
respons
bacterium
lieberman
colleagu
perform
prospect
studi
look
patient
admit
hospit
asthma
exacerb
subject
younger
year
evid
infiltr
chest
imag
exclud
blood
sampl
subject
agematch
control
obtain
admiss
week
later
serolog
test
frequenc
acut
infect
variou
pathogen
includ
virus
bacteria
atyp
bacteria
compar
asthma
control
group
signific
find
includ
detect
influenza
asthmat
versu
control
posit
serolog
test
pneumonia
hospit
asthmat
compar
control
differ
detect
c
pneumonia
group
studi
limit
serolog
diagnosi
infect
investig
conclud
pneumonia
infect
correl
asthma
exacerb
requir
hospit
prospect
analysi
patient
present
emerg
depart
asthma
exacerb
reveal
serolog
evid
acut
atyp
infect
either
c
pneumonia
pneumonia
subject
investig
obtain
peak
flow
measur
present
spirometri
followup
found
signific
reduct
peak
flow
forc
expiratori
flow
second
fev
asthmat
group
atyp
bacteri
infect
compar
asthmat
without
atyp
bacteri
infect
addit
present
sever
asthma
defin
initi
peak
expiratori
flow
pef
less
predict
like
serolog
evid
acut
atyp
bacteri
infect
odd
ratio
specif
limit
studi
address
public
includ
difficulti
diagnosi
use
serolog
small
sampl
size
use
percent
predict
instead
person
best
peak
flow
record
despit
limit
result
support
associ
atyp
bacteri
infect
increas
function
impair
acut
asthma
exacerb
evalu
role
atyp
bacteri
infect
pediatr
asthma
exacerb
biscardi
colleagu
prospect
studi
subject
admit
hospit
sever
asthma
flare
nasopharyng
sampl
obtain
admiss
evalu
presenc
varieti
respiratori
virus
c
pneumonia
pneumonia
acut
infect
diagnos
either
elev
specif
igm
initi
serolog
increas
igg
titer
followup
subject
divid
group
data
analysi
group
includ
subject
acut
exacerb
asthma
group
consist
subject
present
first
onset
wheez
group
compris
control
chronic
stabl
asthma
without
exacerb
previou
month
andor
allerg
rhiniti
group
pneumonia
found
subject
c
pneumonia
detect
subject
exacerb
newonset
wheez
group
pneumonia
detect
subject
statist
signific
differ
compar
group
c
pneumonia
identifi
control
group
evid
pneumonia
followup
subject
group
diagnos
atyp
infect
recurr
asthma
compar
noninfect
subject
group
studi
also
support
potenti
role
atyp
bacteri
infect
acut
asthma
exacerb
interestingli
demonstr
pneumonia
infect
present
larg
proport
children
present
first
asthma
attack
one
hallmark
asthma
exacerb
increas
mucou
product
asthmat
airway
express
increas
level
major
mucin
protein
compar
nonasthmat
control
kraft
colleagu
report
airway
epitheli
cell
patient
asthma
demonstr
increas
express
follow
pneumonia
infect
studi
bronchoscopi
airway
brush
perform
asthmat
subject
nonasthmat
control
subsequ
cultur
airway
epitheli
cell
airliquid
interfac
without
pneumonia
mrna
protein
express
measur
use
pcr
elisa
techniqu
investig
found
signific
increas
mrna
protein
express
asthmat
cell
expos
pneumonia
increas
attenu
cocultur
nfkb
inhibitor
kraft
colleagu
subsequ
postul
increas
mucin
express
asthmat
epitheli
cell
respons
pneumonia
like
involv
signal
nfkb
activ
similarli
morinaga
colleagu
also
found
c
pneumonia
infect
airway
epitheli
cell
led
increas
express
could
reduc
treatment
macrolid
ketolid
studi
also
conclud
erk
extracellular
signalrel
kinas
nfkb
involv
product
trigger
c
pneumonia
variou
human
studi
support
potenti
role
atyp
bacteri
infect
acut
exacerb
asthma
data
support
role
atyp
bacteri
infect
develop
asthma
less
clear
zaitsu
compar
firsttim
wheez
infant
toddler
healthi
control
seroconvers
c
pneumonia
significantli
higher
wheez
subject
control
respect
among
wheez
patient
progress
develop
asthma
statist
like
famili
histori
allerg
diseas
higher
total
ige
furthermor
wheez
patient
c
pneumonia
infect
also
like
develop
asthma
without
infect
rel
risk
kim
colleagu
investig
whether
pneumonia
infect
led
impair
lung
function
thirtyeight
children
hospit
pneumonia
lung
infect
control
children
pneumonia
upper
respiratori
infect
without
lung
involv
complet
highresolut
chest
comput
tomographi
ct
year
infect
note
pneumonia
infect
group
compar
control
group
exhibit
abnorm
ct
find
includ
bronchial
wall
thicken
air
trap
contribut
airflow
obstruct
populationbas
adult
cohort
studi
follow
subject
year
investig
whether
c
pneumonia
infect
confer
risk
develop
asthma
reduc
lung
function
compar
without
serolog
evid
c
pneumonia
although
atyp
bacteri
infect
increas
risk
develop
asthma
investig
found
subject
chronic
c
pneumonia
infect
nonatop
asthma
experienc
faster
declin
fev
compar
asthmat
without
chronic
infect
find
suggest
atyp
bacteri
infect
may
contribut
develop
airflow
obstruct
howev
must
note
sever
publish
studi
support
associ
atyp
bacteri
infect
develop
newonset
obstruct
lung
diseas
consequ
studi
need
clarifi
role
atyp
bacteri
infect
develop
asthma
sever
studi
support
correl
atyp
bacteri
infect
chronic
stabl
asthma
martin
colleagu
look
evid
infect
either
pneumonia
c
pneumonia
pcr
patient
chronic
asthma
nonasthmat
control
found
asthmat
posit
atyp
bacteria
compar
control
pcrposit
asthmat
also
greater
number
tissu
mast
cell
rais
possibl
atyp
bacteri
infect
previous
sensit
host
might
augment
underli
allerg
inflamm
find
wu
colleagu
describ
murin
model
allerg
asthma
gencay
colleagu
evalu
adult
subject
chronic
stabl
asthma
match
control
serolog
evid
infect
c
pneumonia
signific
find
includ
evid
chronic
c
pneumonia
infect
defin
c
pneumoniaespecif
igg
iga
asthmat
versu
control
addit
evid
suggest
atyp
bacteri
infect
may
also
alter
sever
chronic
asthma
review
johnston
martin
atyp
infect
asthma
studi
support
role
atyp
infect
chronic
asthma
sever
found
associ
infect
sever
diseas
hahnand
colleagu
describ
steroiddepend
asthmat
serolog
evid
recent
c
pneumonia
infect
abl
discontinu
oral
steroid
follow
antibiot
therapi
atyp
bacteria
although
base
small
group
investig
question
whether
subject
atyp
bacteri
infect
contribut
steroid
depend
sever
diseas
idea
evalu
black
colleagu
examin
asthmat
serolog
evid
c
pneumonia
infect
collect
clinic
inform
includ
sever
symptom
number
frequenc
hospit
use
asthma
medic
investig
found
correl
use
highdos
inhal
steroid
increas
c
pneumonia
igg
iga
titer
addit
elev
c
pneumonia
igg
lower
fev
compar
percent
predict
although
unclear
whether
use
highdos
inhal
steroid
risk
factor
develop
atyp
bacteri
infect
lung
find
highlight
possibl
atyp
infect
may
influenc
sever
chronic
asthma
black
colleagu
propos
proinflammatori
cytokin
tnfa
rant
regul
upon
activ
normal
tcell
express
secret
induc
infect
may
contribut
diseas
sever
prospect
studi
finnish
cohort
subject
nonatop
asthma
serolog
evid
c
pneumonia
experienc
faster
declin
fev
match
asthmat
without
infect
addit
ten
brink
colleagu
follow
sever
asthmat
crosssect
studi
determin
nonatop
asthmat
serolog
evid
c
pneumonia
infect
significantli
greater
estim
declin
postbronchodil
fev
vital
capac
put
simpli
c
pneumonia
infect
worsen
airflow
obstruct
may
explain
part
infectionrel
airway
remodel
inflamm
cook
colleagu
measur
antibodi
titer
c
pneumonia
acut
asthmat
nonasthmat
control
admit
hospit
although
antibodi
titer
suggest
acut
infect
differ
group
c
pneumonia
antibodi
titer
suggest
prior
infect
found
chronic
sever
asthma
compar
control
adjust
odd
ratio
chlamydi
antigen
respons
activ
host
inflammatori
cascad
respons
infect
immun
respons
direct
chsp
associ
develop
variou
inflammatori
condit
includ
ocular
pelvic
diseas
hahn
peel
test
antibodi
respons
fragment
adult
asthmat
nonasthmat
control
expos
c
pneumonia
found
immunoreact
fragment
associ
increas
airflow
limit
defin
lower
postbronchodil
fev
postul
host
immun
respons
chsp
may
contribut
airway
patholog
thu
worsen
diseas
sever
sever
human
studi
includ
outlin
suggest
associ
atyp
bacteri
infect
sever
asthma
although
studi
suggest
role
atyp
bacteri
infect
asthma
exacerb
chronic
asthma
sever
diseas
use
antibiot
macrolid
direct
still
investig
routin
practic
mechan
antibiot
macrolid
affect
asthma
well
understood
like
multifactori
atyp
bacteri
infect
contribut
asthma
one
imagin
antibioticmedi
clearanc
bacteria
may
benefici
effect
macrolid
like
extend
far
beyond
antimicrobi
properti
numer
studi
character
antiinflammatori
effect
macrolid
includ
reduct
bronchial
epitheli
cell
product
downregul
adhes
molecul
alter
local
inflamm
inhibit
airway
mucou
product
reduct
proinflammatori
cytokin
human
trial
sought
investig
effect
antibiot
therapi
atyp
infect
asthma
outlin
section
asthmat
current
exacerb
enrol
doubleblind
placebocontrol
random
trial
telicast
investig
efficaci
telithromycin
acut
asthma
flare
total
acut
asthmat
enrol
treat
standard
care
plu
day
either
telithromycin
placebo
cultur
serolog
pcr
techniqu
use
evalu
pneumonia
c
pneumonia
primari
outcom
symptom
score
morn
pef
sixtyon
percent
subject
evid
atyp
bacteri
infect
symptom
score
improv
significantli
treatment
group
howev
differ
morn
peak
flow
spirometri
obtain
variou
time
point
includ
baselin
end
treatment
week
end
treatment
fev
improv
l
telithromycin
group
compar
l
control
group
p
howev
differ
longer
seen
week
subgroup
analysi
appear
improv
fev
end
treatment
compar
control
signific
evid
atyp
infect
telicast
trial
demonstr
temporari
clinic
improv
follow
use
antimicrobi
asthma
exacerb
rais
mani
question
includ
would
benefit
therapi
whether
benefit
outweigh
potenti
advers
event
mechan
action
antimicrobi
set
horiguchi
colleagu
examin
effect
sparfloxacin
asthmat
serolog
evid
c
pneumonia
subject
seen
outpati
clinic
random
sparfloxacin
respiratori
quinolon
cover
atyp
bacteria
treatment
total
day
note
treatment
subject
report
decreas
symptom
less
rescu
medic
use
improv
morn
peak
flow
although
suggest
antimicrobi
therapi
improv
asthma
studi
limit
small
sampl
size
bia
may
introduc
nonblind
treatment
black
colleagu
perform
random
doubleblind
placebocontrol
trial
carm
studi
evalu
use
roxithromycin
asthmat
serolog
evid
c
pneumonia
studi
includ
subject
particip
runin
period
week
treatment
either
roxithromycin
placebo
week
followup
primari
end
point
includ
asthma
symptom
score
chang
mean
pef
follow
treatment
differ
symptom
score
roxithromycin
group
experienc
greater
increas
mean
even
pef
lmin
compar
placebo
lmin
longer
seen
month
trial
demonstr
transient
effect
even
pef
follow
antibiot
therapi
kraft
colleagu
studi
effect
clarithromycin
subject
chronic
asthma
subject
complet
methacholin
challeng
spirometri
chest
radiographi
upper
lower
airway
sampl
includ
pcr
analysi
pneumonia
c
pneumonia
subject
random
receiv
clarithromycin
placebo
week
subsequ
evalu
lung
function
measur
inflammatori
mediat
signific
find
includ
evid
pneumonia
andor
c
pneumonia
asthmat
pcrposit
treatment
subject
experienc
increas
fev
ae
ae
l
p
found
pcrneg
subject
treatment
group
control
investig
analyz
bronchoalveolar
lavag
sampl
cytokin
express
found
reduct
tnfa
mrna
pcrposit
asthmat
treat
clarithromycin
reduct
tnfa
mrna
treat
subject
pcrneg
chang
note
inflammatori
cytokin
placebo
group
kraft
colleagu
conclud
clarithromycin
improv
lung
function
patient
evid
atyp
bacteria
addit
reduc
pulmonari
inflammatori
cytokin
pcrposit
neg
subject
studi
also
support
benefici
role
macrolid
asthmat
independ
infect
atyp
bacteria
simpson
colleagu
treat
sever
refractori
asthmat
without
known
pneumonia
c
pneumonia
colon
clarithromycin
placebo
week
found
improv
qualityoflif
score
reduc
sputum
treat
subject
investig
specul
macrolid
may
provid
effect
adjunct
treatment
especi
sever
asthma
presum
neutrophil
diseas
primarili
antiinflammatori
properti
although
studi
suggest
possibl
therapeut
benefit
use
antimicrobi
asthma
remain
unclear
would
benefit
therapi
whether
improv
lung
function
symptom
sustain
recent
cochran
review
evalu
effect
macrolid
chronic
asthma
cite
insuffici
evid
current
recommend
use
topic
clearli
requir
investig
better
understand
role
antimicrobi
therapi
asthma
taken
togeth
studi
suggest
c
pneumonia
pneumonia
infect
frequent
present
acut
exacerb
chronic
asthma
addit
mount
evid
suggest
atyp
bacteri
infect
may
also
affect
sever
diseas
although
causal
role
develop
asthma
prove
signific
limit
exist
diagnos
atyp
bacteri
infect
lung
difficulti
sampl
lack
standard
detect
methodolog
numer
anim
human
studi
outlin
mechan
atyp
bacteri
infect
may
contribut
airway
obstruct
promot
allerg
airway
inflamm
airway
remodel
addit
trial
need
clarifi
role
antimicrobi
atyp
bacteria
asthma
understand
role
atyp
infect
asthma
expand
antimicrobi
antiinflammatori
therapi
target
specif
asthma
phenotyp
may
provid
new
therapeut
option
